Skip to main content

Immunovant, Inc.

For the period ended Mar 31, 2026. Filed May 20, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2026 · Filed May 20, 2026

IMVT$35.15+15.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: May 20, 2026

IMMUNOVANT, INC.
By:/s/ Eric Venker
Eric Venker, M.D., Pharm. D.Chief Executive Officer

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Eric Venker, M.D., Pharm. D. and Tiago Girao, and each one of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in their name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

SIGNATURETITLEDATE
/s/ Eric VenkerChief Executive Officer and DirectorMay 20, 2026
Eric Venker, M.D., Pharm. D.(Principal Executive Officer)
/s/ Tiago GiraoChief Financial OfficerMay 20, 2026
Tiago Girao(Principal Financial and Accounting Officer)
/s/ Frank M. TortiExecutive Chairperson of the Board of DirectorsMay 20, 2026
Frank M. Torti, M.D.
/s/ Jacob BauerDirectorMay 20, 2026
Jacob Bauer
/s/ Andrew FromkinDirectorMay 20, 2026
Andrew Fromkin
/s/ Douglas HughesDirectorMay 20, 2026
Douglas Hughes
/s/ Atul PandeDirectorMay 20, 2026
Atul Pande, M.D.
/s/ Robert SusmanDirectorMay 20, 2026
Robert Susman
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.